featured
ECTRIMS 2024: Disability Progression at Six Months Significantly Lower With Tolebrutinib in Nonrelapsing Secondary Progressive MS
Significantly more patients receiving tolebrutinib versus placebo had confirmed disability improvement at six months
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.